Information on cost-effectiveness: an essential product of a national comparative effectiveness program
- PMID: 18483128
- DOI: 10.7326/0003-4819-148-12-200806170-00222
Information on cost-effectiveness: an essential product of a national comparative effectiveness program
Abstract
The American College of Physicians recently highlighted the need to provide increased information comparing the effectiveness of health care interventions to ensure the rational and effective practice of medicine. Comparative effectiveness refers to the evaluation of the relative clinical effectiveness, safety, and cost of 2 or more medical services, drugs, devices, therapies, or procedures used to treat the same condition. The College further recommended the establishment of an adequately funded, trusted national entity that should prioritize, sponsor, or produce both comparative clinical and cost-effectiveness data. This article addresses the need for the proposed entity to develop cost-effectiveness information. It examines the current reluctance to develop and use cost-effectiveness in the United States; it argues for the importance of this information for all health care stakeholders; and it makes specific recommendations regarding how this information can best be made available and used for the good of the public and our patients.
Comment in
-
Cost-effectiveness information: yes, it's important, but keep it separate, please!Ann Intern Med. 2008 Jun 17;148(12):967-8. doi: 10.7326/0003-4819-148-12-200806170-00224. Epub 2008 May 15. Ann Intern Med. 2008. PMID: 18483126 No abstract available.
-
A menu without prices.Ann Intern Med. 2008 Jun 17;148(12):964-6. doi: 10.7326/0003-4819-148-12-200806170-00223. Epub 2008 May 15. Ann Intern Med. 2008. PMID: 18483127 No abstract available.
-
How can cost-effectiveness information help control unsustainable growth in U.S. health care spending?Ann Intern Med. 2009 Jan 6;150(1):58. doi: 10.7326/0003-4819-150-1-200901060-00015. Ann Intern Med. 2009. PMID: 19124826 No abstract available.
Similar articles
-
Cost-effectiveness information: yes, it's important, but keep it separate, please!Ann Intern Med. 2008 Jun 17;148(12):967-8. doi: 10.7326/0003-4819-148-12-200806170-00224. Epub 2008 May 15. Ann Intern Med. 2008. PMID: 18483126 No abstract available.
-
Comparative effectiveness research.J Am Coll Cardiol. 2009 Mar 17;53(11):973-5. doi: 10.1016/j.jacc.2009.02.010. J Am Coll Cardiol. 2009. PMID: 19281929 No abstract available.
-
Patient assistance programs: information is not our enemy.Health Aff (Millwood). 2009 May-Jun;28(3):843-4. doi: 10.1377/hlthaff.28.3.843. Health Aff (Millwood). 2009. PMID: 19414896 No abstract available.
-
Comparative effectiveness: its role in the healthcare system.Curr Opin Ophthalmol. 2009 May;20(3):188-94. doi: 10.1097/icu.0b013e328329cd59. Curr Opin Ophthalmol. 2009. PMID: 19425205 Review.
-
Understanding cost-effectiveness.Clin Microbiol Infect. 2010 Dec;16(12):1707-12. doi: 10.1111/j.1469-0691.2010.03331.x. Clin Microbiol Infect. 2010. PMID: 20673258 Review.
Cited by
-
Cost-effectiveness of a new strategy to identify uncomplicated gallstone disease patients that will benefit from a cholecystectomy.Surg Endosc. 2017 Jun;31(6):2534-2540. doi: 10.1007/s00464-016-5256-4. Epub 2016 Sep 21. Surg Endosc. 2017. PMID: 27655382 Free PMC article.
-
Real world costs and cost-effectiveness of Rituximab for diffuse large B-cell lymphoma patients: a population-based analysis.BMC Cancer. 2014 Aug 12;14:586. doi: 10.1186/1471-2407-14-586. BMC Cancer. 2014. PMID: 25117912 Free PMC article.
-
Patient-reported outcomes of symptomatic cholelithiasis patients following cholecystectomy after at least 5 years of follow-up: a long-term prospective cohort study.Surg Endosc. 2014 Dec;28(12):3443-50. doi: 10.1007/s00464-014-3619-2. Epub 2014 Jun 21. Surg Endosc. 2014. PMID: 24950724
-
Cost-utility analysis of chemotherapy regimens in elderly patients with stage III colon cancer.Pharmacoeconomics. 2014 Oct;32(10):1005-13. doi: 10.1007/s40273-014-0180-8. Pharmacoeconomics. 2014. PMID: 24920195
-
Cost effectiveness of fesoterodine and tolterodine for the treatment of overactive bladder with urge urinary incontinence in Spain and Finland.Clin Drug Investig. 2014 May;34(5):297-307. doi: 10.1007/s40261-014-0178-1. Clin Drug Investig. 2014. PMID: 24567280 Review.
MeSH terms
LinkOut - more resources
Full Text Sources